Five patients with peripheral neuropathy and benign IgG monoclonal paraproteinaemia are reported, all of whom had a sensorimotor neuropathy with a remitting and relapsing course. The serum paraprotein level did not correlate with the patient's clinical status. Electrophsyiological studies showed marked slowing of conduction velocity and conduction block in four of the patients and mild slowing in the other. Sural nerve biopsies demonstrated a demyelinating neuropathy with inflammatory cell infiltrates in each ofthe five patients. Three of the patients had evidence ofmyelin/Schwann cell reactivity on immunofluorescence studies and in all nerves dense expression of major histocompatability complex class I and II molecules was evident within the endoneurium, on invading mononuclear cells, endothelial cells and Schwann cells. All the patients responded to treatment, plasmapheresis being particularly effective. Four patients have achieved prolonged remissions after all treatment had ceased. These five cases of peripheral neuropathy and IgG paraproteinaemia were identical in their clinical, electrophysiological and pathological features to patients with chronic inflammatory demyelinating polyneuropathy.
The association of benign monoclonal paraproteinaemia or gammopathy (BMG) with peripheral neuropathy is well recognised. [1] [2] [3] Neuropathy is more common in patients with IgM BMG 12 were found to have a peripheral neuropathy associated with a monoclonal gammopathy. In these patients a diagnosis of BMG was made as the uninvolved immunoglobulin subclasses were within the normal range, there was no Bence Jones proteinuria, no evidence of plasma cell infiltration, lymphoma or amyloid deposition on bone marrow aspirate and trephine, and no bony lesions were seen on radiological skeletal survey. Other causes of peripheral neuropathy were excluded. Six patients had IgM paraproteins, 5 had IgG paraproteins and 1 patient had an IgA paraprotein. The 5 patients with IgG paraproteinaemia are the subject of this report; some aspects of the treatment of patients 1 and 3 have appeared in previous publications.67
Electrophysiological studies Nerve conduction studies were performed in the upper and lower limbs. Motor conduction velocity was measured in the median, ulnar and lateral popliteal nerves when recording compound muscle action potentials with bipolar surface electrodes over the abductor pollicis brevis, abductor digiti minimi and extensor digitorum brevis muscles respectively. The median and ulnar sensory nerve action potentials (SNAP) were recorded at the wrist with bipolar surface electrodes after orthodromic stimulation through ring electrodes of the index and little finger respectively. The sural SNAP was recorded with bipolar surface or subcutaneous needle electrodes in the lower calf following orthodromic stimulation of the nerve at the lateral malleolus. Electromyography was performed in 3 of the patients using concentric needle electrodes placed in the intrinsic muscles of the hand and distal muscles in the lower limbs. The results of the nerve conduction studies were compared with results obtained in a population of 20 men and women without symptoms or signs of neurological disease between the ages of 50-80 years.
Histological studies Sural nerve biopsy was performed at the level of the lateral malleolus to obtain 3-4 cm of nerve which was divided into four equal portions. A piece of nerve was fixed in picric acid saline for 24-36 hours, dehydrated in alcohol, embedded in paraffin wax, and cut transversely in serial sections of 5,um. The sections were stained with haematoxylin, counterstained with eosin and examined by light microscopy. A second piece of nerve was fixed for at least 24 hours in 10% buffered formaldehyde (pH 7 0) and then stained for 24 Immunohistochemical studies using monoclonal antibodies to T-cell subsets, macrophages and major histocompatability complexes I and II were performed on all nerves as previously described.8 Evidence of serum anti-myelin activity was also sought in patients 1, 2 and 5 by immunoblot and ELISA. A postmortem preparation of human sciatic nerve myelin, obtained within 12 hours of death, was run on 12-5% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) and the separated proteins transferred electrophoretically to nitrocellulose membranes9. After blocking with 2-5% bovine albumin and 0-02% sodium azide in phosphate buffered saline the nitrocellulose was cut into 3 mm strips which were then incubated in the presence of serum from patients or controls overnight. The strips were washed and then incubated with peroxidase conjugated rabbit antihuman IgG, IgM and IgA and the reaction product revealed by dipping the strips into Chloro-l-naphthol H202 solution. Separate strips after SDS PAGE were stained with Coomassie blue to show separated proteins. For the ELISA assay microtitre plates were coated with purified human myelin and incubated with the test sera. The wells were probed with horseradish peroxidase-anti-IgG, IgM and IgA.
Results
The mean age of the patients at the onset of symptoms was 53-4 years (range 43-73 years). A summary of the clinical course and treatment of patients 1 and 3 is shown in fig 1. Patient 5 had had an upper respiratory infection some weeks before the onset of neurological symptoms but an antecedent illness or vaccination was not reported in the others. The earliest symptoms were sensory in each patient with symmetrical distal limb paraesthesiae and numbness which ascended over weeks or months. Only patient 5 had painful sensory symptoms. Peak disability was reached from 9 to 20 months after the onset of symptoms. There was considerable variation in the degree of motor involvement within the group. Patient 3 had a predominantly sensory neuropathy while weakness developed 7-18 months after the onset of sensory symptoms in the other four patients. Patients 1, 4 and 5 had severe weakness and were bedbound at some time during their illness although none of the patients had significant respiratory muscle weakness. None of the patients had tremor. Cranial nerves were affected in two patients; facial paraesthesiae was reported in patient 3 and orofacial paraesthesiae and vocal cord paresis noted in patient 5 pleocytosis in all patients. The initial serum paraprotein levels were 1 9-9 0 g/l for patients 1, 2, 3 and 5 with IgG K, and 1-0 g/l for patient 4 with IgG e.
All patients relapsed after initially responding to treatment some after their treatment was stopped and others whilst continuing treatment. Reintroduction or intensification of treatment always produced another remission and four of the patients have achieved prolonged remissions requiring no therapy. Prednisone, with or without azathioprine, has generally been used as first line treatment but has required supplementation except in one of the patients (patient 2). Azathioprine produced intolerable nausea in patient 1 to lower paraprotein levels by treatment. There was certainly no evidence of paraprotein levels falling with remission of the neuropathy in our patients with IgG paraprotein, in fact the level tended to increase in 3 of the patients. Nevertheless, there may not necessarily be a strict relationship between serum levels of paraproteins and the intraneural level. The latter will depend upon other factors such as the permeability of the blood-nerve barrier. Inflammatory lesions involving the production of vasoactive amines and cytokines may considerably increase the permeability and allow more antibody access to myelinated fibres. Persistence of motor conduction velocity slowing despite clinical improvement is not surprising as conduction velocity measures the fastest conducting fibres and is not a good measure of the function of the whole nerve. Serial measurement of the amplitude of the CMAP may correlate better with recovery of motor function.
Our patients and many of the cases of IgG BMG associated polyneuropathy reported previously are clinically heterogeneous, and they display the electrophysiological, pathological and treatment responsive features of CIDP.
The distinction between such cases of chronic demyelinating polyneuropathy and CIDP on the basis of an associated IgG BMG may well be artificial. 4' We thank Dr Ray Garrick and Dr Grant Walker for their assistance in documenting the clinical histories of patients 2 and 5, and Ms Julia Baverstock for providing expert technical assistance in the preparation of the sural nerve biopsies.
